Lacosamida Jubilant Pharmaceuticals (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and reduces abnormal neuronal firing. This selective action limits the persistence of sodium currents that contribute to seizure generation.

The appropriate dose of lacosamide is determined by the prescribing clinician based on the patient’s age, renal and hepatic function, and response to therapy. Dosage adjustments may be required for special populations.

The safety of lacosamide in pregnancy and lactation has not been fully established. It is classified as having an unknown pregnancy category, so it should only be used if the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that block fast sodium channels. This can provide additional seizure control in patients who have not responded to other agents, while offering a generally favorable tolerability profile.

Lacosamida Jubilant Pharmaceuticals should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. No refrigeration is required for this oral formulation.

Lacosamide is administered orally, typically as tablets or oral solution, and should be taken with or without food as directed by the prescriber. Consistent dosing times help maintain stable blood levels.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, potential suicidal thoughts or behaviors, severe skin reactions like Stevens‑Johnson syndrome, and rare cases of hepatic injury or blood dyscrasias. Patients should be monitored for these events.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking interacting medications without proper monitoring.